Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories (NY: BIO )

325.29 -3.07 (-0.93%)
Official Closing Price Updated: 7:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 172,218
Open 327.68
Bid (Size) 306.42 (1)
Ask (Size) 350.00 (1)
Prev. Close 328.36
Today's Range 322.25 - 328.44
52wk Range 261.59 - 406.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bio-Rad Reports Second-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire

Performance

YTD
-0.82%
-0.82%
1 Month
+10.07%
+10.07%
3 Month
+13.96%
+13.96%
6 Month
-0.31%
-0.31%
1 Year
-18.09%
-18.09%

More News

Read More
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months
Via Benzinga
Topics Stocks
Exposures US Equities
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Via Benzinga
Bio-Rad Laboratories: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Via TheNewswire.com
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Preview: Bio-Rad Laboratories's Earnings
Via Benzinga
BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Bio-Rad Reports First-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Announces Life Science Group Management Changes
From Bio-Rad Laboratories, Inc.
Via Business Wire
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?
Via Benzinga
Topics Stocks
Exposures US Equities
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
From Bio-Rad Laboratories, Inc.
Via Business Wire
Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
10 S&P 500 Stocks With Over 40% Upside Potential: Hidden Gems Or Value Traps?
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.